Cryoport, Syneos Health Form New CGT Partnership
Cold chain company’s supply chain services experience to help facilitate therapy transport
Cryoport, Inc., a temperature-controlled supply chain solution provider for the life sciences industry, has established a new strategic partnership with Syneos Health, a biopharma clinical and commercial solutions organization.
The agreement aims to support the advancement of cell and gene therapies (CGTs), combining Syneos’ clinical development experience with Cryoport’s branded platform, IntegriCell, which provides standardized apheresis collection through BioLife Cellular Therapy Services (part of Takeda), cryopreservation services, risk mitigation services, logistics support, and secondary packaging.
"Leveraging our relationship with Cryoport, Syneos Health will help deliver seamless integration and insights for key services for cell and gene trial operations to biopharmaceutical customers,” says Michael Brooks, COO of Syneos Health. “This partnership will further help to accelerate treatment timelines and improve outcomes by expanding patient access to these life-changing therapies worldwide."
Read more about the partnership here.
